Nagiec MM, Skepner AP, Negri J, et al. Modulators of hepatic lipoprotein metabolism identified in a search for small-molecule inducers of tribbles pseudokinase 1 expression. PLoS One. 2015;10(3):e0120295. doi:10.1371/journal.pone.0120295.
Lin WM, Baker AC, Beroukhim R, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008;68(3):664-73. doi:10.1158/0008-5472.CAN-07-2615.
Jalili A, Wagner C, Pashenkov M, et al. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. J Natl Cancer Inst. 2012;104(21):1673-9. doi:10.1093/jnci/djs373.
Johannessen CM, Johnson LA, Piccioni F, et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013;504(7478):138-42. doi:10.1038/nature12688.
Chmielecki J, Meyerson M. DNA sequencing of cancer: what have we learned? Annu Rev Med. 2014;65:63-79. doi:10.1146/annurev-med-060712-200152.
Moody SE, Schinzel AC, Singh S, et al. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene. 2015;34(16):2061-71. doi:10.1038/onc.2014.153.
Chen G, McQuade JL, Panka DJ, et al. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016;2(8):1056-64. doi:10.1001/jamaoncol.2016.0509.
Kim MJ, Biag J, Fass DM, et al. Functional analysis of rare variants found in schizophrenia implicates a critical role for GIT1-PAK3 signaling in neuroplasticity. Mol Psychiatry. 2017;22(3):417-429. doi:10.1038/mp.2016.98.